126 related articles for article (PubMed ID: 30624446)
21. Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing system.
Aung KL; Donald E; Ellison G; Bujac S; Fletcher L; Cantarini M; Brady G; Orr M; Clack G; Ranson M; Dive C; Hughes A
J Mol Diagn; 2014 May; 16(3):343-9. PubMed ID: 24631158
[TBL] [Abstract][Full Text] [Related]
22. SNPase-ARMS qPCR: Ultrasensitive Mutation-Based Detection of Cell-Free Tumor DNA in Melanoma Patients.
Stadler J; Eder J; Pratscher B; Brandt S; Schneller D; Müllegger R; Vogl C; Trautinger F; Brem G; Burgstaller JP
PLoS One; 2015; 10(11):e0142273. PubMed ID: 26562020
[TBL] [Abstract][Full Text] [Related]
23. Decalcification can cause the failure of BRAF molecular analyses and anti-BRAFV600E VE1 immunohistochemistry.
Bourhis A; Le Flahec G; Uguen A
Pathol Int; 2019 Apr; 69(4):219-223. PubMed ID: 30843305
[TBL] [Abstract][Full Text] [Related]
24. Intra- and Inter-Tumoral Homogeneity of BRAF(V600E) Mutations in Melanoma Tumors.
Riveiro-Falkenbach E; Villanueva CA; Garrido MC; Ruano Y; García-Martín RM; Godoy E; Ortiz-Romero PL; Ríos-Martín JJ; Santos-Briz A; Rodríguez-Peralto JL
J Invest Dermatol; 2015 Dec; 135(12):3078-3085. PubMed ID: 26083553
[TBL] [Abstract][Full Text] [Related]
25. BRAFV600E immunopositive melanomas show low frequency of heterogeneity and association with epithelioid tumor cells: a STROBE-compliant article.
Verlinden I; van den Hurk K; Clarijs R; Willig AP; Stallinga CMHA; Roemen GMJM; van den Oord JJ; Zur Hausen A; Speel EM; Winnepenninckx VJL
Medicine (Baltimore); 2014 Dec; 93(28):e285. PubMed ID: 25526463
[TBL] [Abstract][Full Text] [Related]
26. Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma.
Calapre L; Warburton L; Millward M; Ziman M; Gray ES
Cancer Lett; 2017 Sep; 404():62-69. PubMed ID: 28687355
[TBL] [Abstract][Full Text] [Related]
27. A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan.
Huang WK; Kuo TT; Wu CE; Cheng HY; Hsieh CH; Hsieh JJ; Shen YC; Hou MM; Hsu T; Chang JW
Asia Pac J Clin Oncol; 2016 Dec; 12(4):403-408. PubMed ID: 27488807
[TBL] [Abstract][Full Text] [Related]
28. VE1 Immunohistochemistry Fails to Detect Most of the Non-BRAFV600E Mutations in Melanoma.
Uguen A; Uguen M
Appl Immunohistochem Mol Morphol; 2016; 24(10):e98-e99. PubMed ID: 26894646
[No Abstract] [Full Text] [Related]
29. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors.
Sanmamed MF; Fernández-Landázuri S; Rodríguez C; Zárate R; Lozano MD; Zubiri L; Perez-Gracia JL; Martín-Algarra S; González A
Clin Chem; 2015 Jan; 61(1):297-304. PubMed ID: 25411185
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature.
Anwar MA; Murad F; Dawson E; Abd Elmageed ZY; Tsumagari K; Kandil E
J Surg Res; 2016 Jun; 203(2):407-15. PubMed ID: 27363650
[TBL] [Abstract][Full Text] [Related]
32. Highly Concordant Results Between Immunohistochemistry and Molecular Testing of Mutated V600E BRAF in Primary and Metastatic Melanoma.
Manfredi L; Meyer N; Tournier E; Grand D; Uro-Coste E; Rochaix P; Brousset P; Lamant L
Acta Derm Venereol; 2016 Jun; 96(5):630-4. PubMed ID: 26695089
[TBL] [Abstract][Full Text] [Related]
33. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
Hugdahl E; Kalvenes MB; Puntervoll HE; Ladstein RG; Akslen LA
Br J Cancer; 2016 Mar; 114(7):801-8. PubMed ID: 26924424
[TBL] [Abstract][Full Text] [Related]
34. A comparison of high resolution melting, allele-specific priming and Sanger sequencing for the detection of BRAFV600E mutation in hairy cell leukaemia from different haematological specimens.
So CC; Chan A; Chung LP; Siu L; Wong WS; Wong KF
Pathology; 2014 Oct; 46(6):533-7. PubMed ID: 25158814
[TBL] [Abstract][Full Text] [Related]
35. [Utility and evaluation of immunohistochemical detection of BRAF V600E mutation in melanoma].
Lyu JJ; Kong YY; Cai X; Shen XX; Lu YW; Ren M
Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):548-552. PubMed ID: 28810295
[No Abstract] [Full Text] [Related]
36. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.
Ferrari de Andrade L; Ngiow SF; Stannard K; Rusakiewicz S; Kalimutho M; Khanna KK; Tey SK; Takeda K; Zitvogel L; Martinet L; Smyth MJ
Cancer Res; 2014 Dec; 74(24):7298-308. PubMed ID: 25351955
[TBL] [Abstract][Full Text] [Related]
37. Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation in circulating tumor cells from metastatic melanoma patients.
Hofman V; Ilie M; Long-Mira E; Giacchero D; Butori C; Dadone B; Selva E; Tanga V; Passeron T; Poissonnet G; Emile JF; Lacour JP; Bahadoran P; Hofman P
J Invest Dermatol; 2013 May; 133(5):1378-81. PubMed ID: 23303445
[No Abstract] [Full Text] [Related]
38. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.
Behling F; Barrantes-Freer A; Skardelly M; Nieser M; Christians A; Stockhammer F; Rohde V; Tatagiba M; Hartmann C; Stadelmann C; Schittenhelm J
Diagn Pathol; 2016 Jun; 11(1):55. PubMed ID: 27350555
[TBL] [Abstract][Full Text] [Related]
39. In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAFV600E in melanoma.
Guo X; Xu Y; Zhao Z
Mol Cancer; 2015 Mar; 14():60. PubMed ID: 25890285
[TBL] [Abstract][Full Text] [Related]
40. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma.
Sensi M; Nicolini G; Petti C; Bersani I; Lozupone F; Molla A; Vegetti C; Nonaka D; Mortarini R; Parmiani G; Fais S; Anichini A
Oncogene; 2006 Jun; 25(24):3357-64. PubMed ID: 16462768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
